US OptionsDetailed Quotes

PSTX240816C5000

Watchlist

0.09
+0.04+80.00%

15min DelayClose Jul 26 15:59 ET

0.09High0.09Low

Poseida Therapeutics Stock Discussion

Jaguar8

May 1 12:31

$Poseida Therapeutics(PSTX.US)$
NEWS
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology

Jaguar8

Apr 8 11:49

$Poseida Therapeutics(PSTX.US)$
NEWS
Poseida Therapeutics (PSTX) presents promising data on P-BCMA-ALLO1 for relapsed/refractory multiple myeloma, achieving clinical responses and good tolerability. The study highlights the need for higher lymphodepletion doses in solid tumors. The company continues to innovate in allogeneic CAR-T therapies for cancer treatment.

Moomoo AI

Mar 25 15:09

Dr. Rizvi's appointment, with his vast experience in cancer treatments, is a major asset to Poseida Therapeutics. His expertise will be crucial as the company progresses its clinical stage CAR-T portfolio.

Press Release: Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer

Moomoo AI

Dec 18, 2023 05:25

Poseida Therapeutics' P/S ratio remains modest despite the recent stock price surge. With inferior revenue forecasts and expected revenue decline, it's unlikely for a significant increase in share price in the near future.